MONTREAL, Canada, August 4th, 2025 – Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an exclusive distribution agreement with Neuraxpharm, S.L.U. (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, headquartered in Düsseldorf, Germany.

Under the terms of the agreement, Pendopharm® will be responsible for the commercialization of Buccolam® in Canada. 

Pendopharm® is pleased to announce that Health Canada has authorized Buccolam®.

“This partnership represents Pendopharm’s commitment to bringing medicines to Canadian patients,” said Jad Isber, Vice President & General Manager of Pendopharm®. “We look forward to working with Canadian neurologists and pediatricians.

Dr. Maximilian von Wülfing, Chief Operating Officer of Neuraxpharm, said: “Through its network of strategic partnerships around the world, Neuraxpharm is committed to expanding access to medicines. Our collaboration with Pendopharm further strengthens our position as a global CNS specialist.”

About Pendopharm®

Pendopharm, specialty division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm® has extensive experience and knowledge to successfully manage its growing product portfolio.

For more information, please visit www.pendopharm.com.

For media inquiries, please contact MediaInquiries@pharmascience.com.

© 2025 Pendopharm, division of Pharmascience Inc. All rights reserved.

About Pharmascience Inc.

Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers medicines to over 50 countries worldwide. Pharmascience Inc.’s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients’ needs. 

About Neuraxpharm 

Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years and is expanding its portfolio through its pipeline, partnerships and acquisitions. 

The company has 1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira.

Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain.

For more information, please contact: Neuraxpharm@optimumcomms.com 

Pendopharm® and Design are registered trademarks owned by Finchley Research and Development Inc., used under license by Pharmascience Inc. Buccolam® is a registered trademark owned by Neuraxpharm Pharmaceuticals, S.L., used under license by Pendopharm, a division of Pharmascience Inc.